These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21649491)

  • 1. High-resolution mass spectrometry will dramatically change our drug-discovery bioanalysis procedures.
    Korfmacher W
    Bioanalysis; 2011 Jun; 3(11):1169-71. PubMed ID: 21649491
    [No Abstract]   [Full Text] [Related]  

  • 2. Free versus total ligand-binding assays: points to consider in biotherapeutic drug development.
    Yang J; Quarmby V
    Bioanalysis; 2011 Jun; 3(11):1163-5. PubMed ID: 21649490
    [No Abstract]   [Full Text] [Related]  

  • 3. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening.
    Tolonen A; Turpeinen M; Pelkonen O
    Drug Discov Today; 2009 Feb; 14(3-4):120-33. PubMed ID: 19059358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass spectrometry imaging in drug development.
    Nilsson A; Goodwin RJ; Shariatgorji M; Vallianatou T; Webborn PJ; Andrén PE
    Anal Chem; 2015 Feb; 87(3):1437-55. PubMed ID: 25526173
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug bioanalysis and biomarker discovery at the Commissariat à l'énergie atomique et aux énergies alternatives.
    Ezan E; Becher F; Benech H; Fenaille F; Junot C; Mabondzo A; Pruvost A
    Bioanalysis; 2010 Apr; 2(4):713-7. PubMed ID: 21083268
    [No Abstract]   [Full Text] [Related]  

  • 6. A reflection on fit-for-purpose metabolite investigation at different stages of drug development.
    Leclercq L
    Bioanalysis; 2014 Mar; 6(5):591-4. PubMed ID: 24620799
    [No Abstract]   [Full Text] [Related]  

  • 7. Technologies and strategies to characterize and quantitate metabolites in drug discovery and development.
    Ravindran S; Jadhav A; Surve P; Lonsane G; Honrao P; Nanda B
    Biomed Chromatogr; 2014 Nov; 28(11):1547-53. PubMed ID: 25175001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel LC-MS approach for the detection of metabolites in DMPK studies.
    Plumb RS; Mather J; Little D; Rainville PD; Twohig M; Harland G; Kenny DJ; Nicholson JK; Wilson ID; Kass IJ
    Bioanalysis; 2010 Oct; 2(10):1767-78. PubMed ID: 21083328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outsource-ability of high-resolution MS-based DMPK assays.
    Rago B; Negahban A
    Bioanalysis; 2016 Aug; 8(16):1641-4. PubMed ID: 27416917
    [No Abstract]   [Full Text] [Related]  

  • 10. Discovery bioanalysis. Foreward.
    Shou WZ
    Bioanalysis; 2012 May; 4(9):983-4. PubMed ID: 22612675
    [No Abstract]   [Full Text] [Related]  

  • 11. The emergence of high-resolution MS as the premier analytical tool in the pharmaceutical bioanalysis arena.
    Ramanathan R; Korfmacher W
    Bioanalysis; 2012 Mar; 4(5):467-9. PubMed ID: 22409544
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry.
    Hopfgartner G; Bourgogne E
    Mass Spectrom Rev; 2003; 22(3):195-214. PubMed ID: 12838545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved investigations in drug safety by more in-depth individual pharmacokinetics using high-resolution mass spectrometry.
    Rochat B; Dahmane E; Zaman K; Csajka C
    Ther Drug Monit; 2015 Apr; 37(2):141-6. PubMed ID: 25768971
    [No Abstract]   [Full Text] [Related]  

  • 14. Capillary electrophoresis-mass spectrometry, an attractive tool for drug bioanalysis and biomarker discovery.
    Servais AC; Crommen J; Fillet M
    Electrophoresis; 2006 Jul; 27(13):2616-29. PubMed ID: 16817163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development.
    Yu XQ; Wilson AG
    Future Med Chem; 2010 Jun; 2(6):923-8. PubMed ID: 21426110
    [No Abstract]   [Full Text] [Related]  

  • 16. Chiral liquid chromatography-tandem mass spectrometric methods for stereoisomeric pharmaceutical determinations.
    Chen J; Korfmacher WA; Hsieh Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jun; 820(1):1-8. PubMed ID: 15866486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging applications for high-resolution MS in discovery bioanalysis.
    Emary WB; Zhang NR
    Bioanalysis; 2011 Nov; 3(22):2485-9. PubMed ID: 22122595
    [No Abstract]   [Full Text] [Related]  

  • 18. Imaging and spatially resolved quantification of drug distribution in tissues by mass spectrometry.
    Prideaux B; Lenaerts A; Dartois V
    Curr Opin Chem Biol; 2018 Jun; 44():93-100. PubMed ID: 29957376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Principles and applications of LC-MS in new drug discovery.
    Korfmacher WA
    Drug Discov Today; 2005 Oct; 10(20):1357-67. PubMed ID: 16253874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future trends in the application of HPLC-MS to metabolite-identification studies.
    Castro-Perez JM
    Drug Discov Today; 2007 Mar; 12(5-6):249-56. PubMed ID: 17331890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.